AIM:To explore the therapeutic effect and safety evaluation of Qiming Granule on non-proliferative diabetic retinopathy(NPDR).

METHODS: Totally 94 cases(120 eyes)of NPDR patients treated in endocrinology department of our hospital from January 2016 to November 2017 were selected and randomly divided into the control group(n=47, 60 eyes)and the experimental group(n=47, 60 eyes). The control group was treated with calcium dobesilate, and the experimental group was treated with Qiming granule. The clinical efficacy, central macular thickness, retinal circulation time, best corrected visual acuity and adverse reactions between two groups were evaluated and compared after 6-month treatment.

RESULTS: Before treatment, there were no significant difference in central macular thickness, retinal circulation time, and best corrected visual acuity between two groups(P>0.05). After treatment, comparing with the control group, the retinal circulation time were not significantly different, the improvement of macular edema and the recovery of visual acuity were significantly better in the experimental group. The total effective rate of the experimental group was 97%, which was significantly higher than that of the control group(57%), and the incidence of adverse reactions was significantly decreased. The difference was statistically significant(P<0.05).

CONCLUSION: The therapeutic effect of Qiming Granule on NPDR is better than that of calcium dobesilate. Qiming Granule can improve visual acuity, macular edema, the retinal circulation time with less adverse reactions.